A Phase 1 Exploratory Study of the Safety and ex Vivo Fluorescence of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Solid Tumors Undergoing Surgery

Trial Profile

A Phase 1 Exploratory Study of the Safety and ex Vivo Fluorescence of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Solid Tumors Undergoing Surgery

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Blaze Bioscience
  • Most Recent Events

    • 27 Apr 2017 Status changed from active, no longer recruiting to completed, as reported in a Blaze Bioscience media release.
    • 27 Apr 2017 According to a Blaze Bioscience media release, this study was conducted at University of Washington Medical Center under the direction of principal investigator David Byrd. This study was supported by a Small Business Innovation Research (SBIR) Phase II contract by the National Cancer Institute (NCI).
    • 27 Apr 2017 According to a Blaze Bioscience media release, data (n=23) from this trial will be presented at the 18th Annual American Society of Breast Surgeons (ASBrS) Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top